RecruitingPhase 1NCT07077434
A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors
A Phase 1 Open-Label, Multi-Center Study to Evaluate Pharmacokinetics, Safety and Tolerability of BMS-986504 in Japanese and Chinese Participants With Advanced Solid Tumors With Homozygous MTAP Deletion
Sponsor
Bristol-Myers Squibb
Enrollment
32 participants
Start Date
Oct 15, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the safety, tolerability and drug levels of BMS-986504 in participants with advanced solid tumors.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Participants must have histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue.
- Participants must have unresectable or metastatic disease not amenable to curative therapies after progression on prior therapies at the time of enrollment.
- Participants must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Participants must have presence of at least one measurable tumor lesion per RECIST 1.1 at baseline.
Exclusion Criteria4
- Participants must not have prior treatment with a Protein arginine methyltransferase 5 (PRMT5) or Methionine adenosyltransferase 2A (MAT2A) inhibitor.
- Participants must not have active brain metastases or carcinomatous meningitis.
- Participants must not have a history of gastrointestinal disease or other gastrointestinal conditions (e.g., uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications.
- Participants must not have known severe hypersensitivity to study treatment and/or any of its excipients.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBMS-986504
Specified dose on specified days
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07077434
Related Trials
NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors
NCT075614371 location
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
NCT0641368011 locations
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT042224132 locations
A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
NCT074390941 location
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT067232367 locations